A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer

BACKGROUND: Locally advanced pancreatic cancer (LAPC) has a dismal prognosis with current treatment modalities and one-third of patients die from local progression of disease. Preclinical studies with orthotopic PC demonstrated dramatic synergy between radiotherapy (RT) and the poly(ADP-ribose) poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuli, R., Shiao, S.L., Nissen, N., Tighiouart, M., Kim, S., Osipov, A., Bryant, M., Ristow, L., Placencio-Hickok, V.R., Hoffman, D., Rokhsar, S., Scher, K., Klempner, S.J., Noe, P., Davis, M.J., Wachsman, A., Lo, S., Jamil, L., Sandler, H., Piantadosi, S., Hendifar, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412162/
https://www.ncbi.nlm.nih.gov/pubmed/30635165
http://dx.doi.org/10.1016/j.ebiom.2018.12.060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412162/
https://www.ncbi.nlm.nih.gov/pubmed/30635165
http://dx.doi.org/10.1016/j.ebiom.2018.12.060

Ejemplares similares